The trading price of Abbott Laboratories (NYSE:ABT) floating lower at last check on current market day and closing at $136.15, -1.04% lower than its previous close.
The company’s P/E ratio in the trailing 12-month period was 17.77. In examining the 52-week price action we see that the stock hit a 52-week high of $141.23 and a 52-week low of $99.71. Over the past month, the stock has gained 6.00% in value.
Abbott Laboratories, whose market valuation is $236.14 billion at the time of this writing, is expected to release its quarterly earnings report in April. The dividend yield on the company stock is 1.65%, while its Forward Dividend ratio is 2.24. Investors’ optimism about the company’s current quarter earnings report is understandable. Analysts have predicted the quarterly earnings per share to grow by 1.06 per share this quarter, however they have predicted annual earnings per share of 5.15 for current year and 5.67 for next year.
Analysts have forecast the company to bring in revenue of 10.38B for the current quarter, with the likely lows of 9.96B and highs of 10.72B. From the analysts’ viewpoint, the consensus estimate for the company’s annual revenue is 44.38B.
On the technical side, indicators suggest ABT has a 100% Buy on average for the short term. According to the data of the stock’s medium term indicators, the stock is currently averaging as a 100% Buy, while an average of long term indicators suggests that the stock is currently 100% Buy.
Here is the average analyst rating on the stock as represented by 1.00 to 5.00, with the extremes of 1.00 and 5.00 suggesting the stock should be considered as either strong buy or strong sell respectively. The number of analysts that have assigned ABT a recommendation rating is 13. Out of them, 1 rate it a Hold, while 12 recommend Buy, whereas 0 assign an Overweight rating. 0 analyst(s) have tagged Abbott Laboratories (ABT) as Underweight, while 0 advise Sell. Analysts have rated the stock Buy, likely urging investors to take advantage of the opportunity to add to their holdings of the company’s shares.
If we dig deeper into the stock’s outlook, we see that the stock’s PEG is 1.67, which symbolizes a positive outlook. A quick review shows that ABT’s price is currently 1.99% off the SMA20 and 9.65% off the SMA50. The RSI metric on the 14-day chart is currently showing 62.91, and weekly volatility stands at 2.05%. When measured over the past 30 days, the indicator reaches 1.91%. Abbott Laboratories (NYSE:ABT)’s beta value is currently sitting at 0.80, while the Average True Range indicator is currently displaying 2.55. With analysts defining $24.01-$139 as the low and high price targets, we arrive at a consensus price target of $130 for the trailing 12-month period. The current price is about 82.37% off the estimated low and -2.09% off the forecast high, based on this estimate. Investors will be thrilled if ABT’s share price rises to $130, which is the median consensus price. At that level, ABT’s share price would be 4.52% above current price.
To see how Abbott Laboratories stock has been performing today in comparison to its peers in the industry, here are the numbers: ABT stock’s performance was -1.04% at last check in today’s session, and 14.78% in the past year. Abbott Laboratories has a P/E ratio of 17.77, compared to Johnson & Johnson’s 28.38 and Rogers Corp.’s 55.12.
An evaluation of the daily trading volume of Abbott Laboratories (NYSE:ABT) indicates that the 3-month average is 6.07 million.
Currently, records show that 1.73 billion of the company’s shares remain outstanding. The insiders hold 0.67% of outstanding shares, whereas institutions hold 78.71%. However, since the stock’s price has seen 20.37% year-to-date, investors’ interest is likely to be reignited due to its potential to move even higher.
